GC Biopharma Statistics

Total Valuation

GC Biopharma has a market cap or net worth of KRW 1.45 trillion. The enterprise value is 2.63 trillion.

Market Cap	1.45T
Enterprise Value	2.63T

Important Dates

The last earnings date was Thursday, May 15, 2025.

Earnings Date	May 15, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

GC Biopharma has 11.41 million shares outstanding. The number of shares has increased by 0.00% in one year.

Current Share Class	11.41M
Shares Outstanding	11.41M
Shares Change (YoY)	+0.00%
Shares Change (QoQ)	-0.01%
Owned by Insiders (%)	0.95%
Owned by Institutions (%)	17.21%
Float	5.45M

Valuation Ratios

The trailing PE ratio is 50.54 and the forward PE ratio is 111.19.

PE Ratio	50.54
Forward PE	111.19
PS Ratio	0.85
PB Ratio	0.99
P/TBV Ratio	1.75
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.66, with an EV/FCF ratio of -24.02.

EV / Earnings	91.41
EV / Sales	1.54
EV / EBITDA	18.66
EV / EBIT	45.90
EV / FCF	-24.02

Financial Position

The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.71.

Current Ratio	1.36
Quick Ratio	0.49
Debt / Equity	0.71
Debt / EBITDA	7.55
Debt / FCF	-9.58
Interest Coverage	1.27

Financial Efficiency

Return on equity (ROE) is 0.70% and return on invested capital (ROIC) is 1.43%.

Return on Equity (ROE)	0.70%
Return on Assets (ROA)	1.21%
Return on Invested Capital (ROIC)	1.43%
Return on Capital Employed (ROCE)	2.79%
Revenue Per Employee	849.61M
Profits Per Employee	14.30M
Employee Count	2,009
Asset Turnover	0.60
Inventory Turnover	1.64

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +13.67% in the last 52 weeks. The beta is 1.41, so GC Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.41
52-Week Price Change	+13.67%
50-Day Moving Average	123,514.00
200-Day Moving Average	144,014.00
Relative Strength Index (RSI)	56.74
Average Volume (20 Days)	25,960

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GC Biopharma had revenue of KRW 1.71 trillion and earned 28.73 billion in profits. Earnings per share was 2,517.06.

Revenue	1.71T
Gross Profit	506.89B
Operating Income	55.02B
Pretax Income	7.24B
Net Income	28.73B
EBITDA	138.55B
EBIT	55.02B
Earnings Per Share (EPS)	2,517.06

Full Income Statement

Balance Sheet

The company has 91.03 billion in cash and 1.05 trillion in debt, giving a net cash position of -955.68 billion or -83,735.22 per share.

Cash & Cash Equivalents	91.03B
Total Debt	1.05T
Net Cash	-955.68B
Net Cash Per Share	-83,735.22
Equity (Book Value)	1.47T
Book Value Per Share	109,602.70
Working Capital	378.13B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -77.24 billion and capital expenditures -32.07 billion, giving a free cash flow of -109.31 billion.

Operating Cash Flow	-77.24B
Capital Expenditures	-32.07B
Free Cash Flow	-109.31B
FCF Per Share	-9,577.39

Full Cash Flow Statement

Margins

Gross margin is 29.70%, with operating and profit margins of 3.22% and 1.68%.

Gross Margin	29.70%
Operating Margin	3.22%
Pretax Margin	0.42%
Profit Margin	1.68%
EBITDA Margin	8.12%
EBIT Margin	3.22%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 1,500.00, which amounts to a dividend yield of 1.18%.

Dividend Per Share	1,500.00
Dividend Yield	1.18%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	67.99%
Buyback Yield	-0.00%
Shareholder Yield	1.20%
Earnings Yield	1.98%
FCF Yield	-7.53%

Dividend Details

Stock Splits

The last stock split was on June 7, 2013. It was a forward split with a ratio of 1.05.

Last Split Date	Jun 7, 2013
Split Type	Forward
Split Ratio	1.05

Scores

GC Biopharma has an Altman Z-Score of 1.78. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.78
Piotroski F-Score	n/a